CONTEXT: Low sex hormone levels have been associated with the metabolic syndrome (MetS). OBJECTIVES: Our objective was to determine whether the association between sex hormone levels and MetS varies by race/ethnicity among men and to investigate the relationship of sex hormones and individual components of MetS. DESIGN: We conducted a population-based observational survey. PARTICIPANTS: A multistage stratified design was used to recruit a random sample of 2301 racially/ethnically diverse men age 30-79 yr. Blood samples were obtained on 1899 men. Analyses were conducted on 1885 men with complete data on total testosterone (T), free T, and SHBG. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURE: MetS was defined using a modification of the Adult Treatment Panel III guidelines. The association between MetS and sex hormone levels was assessed using odds ratios and 95% confidence intervals estimated using logistic regression models. RESULTS: A strong inverse association was observed, in both bivariate and multivariate analyses, between hormone levels and MetS. The odds of MetS increased about two-fold with a 1 sd decrease in hormone levels. The association between sex hormones and MetS was statistically significant across racial/ethnic groups. Although the magnitude of this association was largest among White men, racial/ethnic differences were not statistically significant. The strength of the association of sex hormones with individual components of MetS varied; stronger associations were observed with waist circumference and dyslipidemia and more modest associations with diabetes and elevated blood sugar. CONCLUSIONS: A robust, dose-response relationship between sex hormone levels and odds of the metabolic syndrome in men is consistent across racial/ethnic groups.
CONTEXT: Low sex hormone levels have been associated with the metabolic syndrome (MetS). OBJECTIVES: Our objective was to determine whether the association between sex hormone levels and MetS varies by race/ethnicity among men and to investigate the relationship of sex hormones and individual components of MetS. DESIGN: We conducted a population-based observational survey. PARTICIPANTS: A multistage stratified design was used to recruit a random sample of 2301 racially/ethnically diverse men age 30-79 yr. Blood samples were obtained on 1899 men. Analyses were conducted on 1885 men with complete data on total testosterone (T), free T, and SHBG. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURE: MetS was defined using a modification of the Adult Treatment Panel III guidelines. The association between MetS and sex hormone levels was assessed using odds ratios and 95% confidence intervals estimated using logistic regression models. RESULTS: A strong inverse association was observed, in both bivariate and multivariate analyses, between hormone levels and MetS. The odds of MetS increased about two-fold with a 1 sd decrease in hormone levels. The association between sex hormones and MetS was statistically significant across racial/ethnic groups. Although the magnitude of this association was largest among White men, racial/ethnic differences were not statistically significant. The strength of the association of sex hormones with individual components of MetS varied; stronger associations were observed with waist circumference and dyslipidemia and more modest associations with diabetes and elevated blood sugar. CONCLUSIONS: A robust, dose-response relationship between sex hormone levels and odds of the metabolic syndrome in men is consistent across racial/ethnic groups.
Authors: Daniel Einhorn; Gerald M Reaven; Rhoda H Cobin; Earl Ford; Om P Ganda; Yehuda Handelsman; Richard Hellman; Paul S Jellinger; David Kendall; Ronald M Krauss; Naomi D Neufeld; Steven M Petak; Helena W Rodbard; John A Seibel; Donald A Smith; Peter W F Wilson Journal: Endocr Pract Date: 2003 May-Jun Impact factor: 3.443
Authors: Henry A Feldman; Christopher Longcope; Carol A Derby; Catherine B Johannes; Andre B Araujo; Andrea D Coviello; William J Bremner; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: A Elisabeth Hak; Jacqueline C M Witteman; Frank H de Jong; Mirjam I Geerlings; Albert Hofman; Huibert A P Pols Journal: J Clin Endocrinol Metab Date: 2002-08 Impact factor: 5.958
Authors: Naveed Sattar; Allan Gaw; Olga Scherbakova; Ian Ford; Denis St J O'Reilly; Steven M Haffner; Chris Isles; Peter W Macfarlane; Chris J Packard; Stuart M Cobbe; James Shepherd Journal: Circulation Date: 2003-07-14 Impact factor: 29.690
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Andre B Araujo; Julia M Dixon; Elizabeth A Suarez; M Hassan Murad; Lin T Guey; Gary A Wittert Journal: J Clin Endocrinol Metab Date: 2011-08-03 Impact factor: 5.958
Authors: Matthew J Magee; Argita D Salindri; Nang Thu Thu Kyaw; Sara C Auld; J Sonya Haw; Guillermo E Umpierrez Journal: Curr Diab Rep Date: 2018-08-09 Impact factor: 4.810
Authors: Mohammad Abu Zaid; Wambui G Gathirua-Mwangi; Chunkit Fung; Patrick O Monahan; Omar El-Charif; Annalynn M Williams; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra K Althouse; Shirin Ardeshir-Rouhani-Fard; Paul C Dinh; Howard D Sesso; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis Journal: J Natl Compr Canc Netw Date: 2018-03 Impact factor: 11.908
Authors: Robin Haring; Henry Völzke; Stephan B Felix; Sabine Schipf; Marcus Dörr; Dieter Rosskopf; Matthias Nauck; Christof Schöfl; Henri Wallaschofski Journal: Diabetes Date: 2009-07-06 Impact factor: 9.461